European Journal of Cancer
Volume 46, Issue 1 , Pages 21-32 , January 2010

Modelling the genesis and treatment of cancer: The potential role of physiologically based pharmacodynamics

  • Jean-Louis Steimer

      Affiliations

    • Novartis Pharma AG, Basel, Switzerland
    • ,
  • Svein G. Dahl

      Affiliations

    • Department of Pharmacology, Institute of Medical Biology, University of Tromsø, Norway
    • ,
  • Dinesh P. De Alwis

      Affiliations

    • Eli Lilly & Company, Surrey, UK
    • ,
  • Ursula Gundert-Remy

      Affiliations

    • Bundesinstitut für Risikobewertung, Berlin, Germany
    • ,
  • Mats O. Karlsson

      Affiliations

    • Uppsala University, Uppsala, Sweden
    • ,
  • Jirina Martinkova

      Affiliations

    • Charles University of Prague, Faculty of Medicine in Hradec Kralove, Hradec Kralove, Czech Republic
    • ,
  • Leon Aarons

      Affiliations

    • University of Manchester, Manchester, United Kingdom
    • Corresponding Author InformationCorresponding author: Address: University of Manchester, School of Pharmacy and Pharmaceutical Sciences, Oxford Road, M13 9PL Manchester, United Kingdom. Tel.: +44 161 275 2357; fax: +44 161 275 2396.
    • ,
  • Hans-Jürgen Ahr

      Affiliations

    • Bayer Health Care, Leverkusen, Germany
    • ,
  • Jean Clairambault

      Affiliations

    • INRIA, Paris, France
    • ,
  • Gilles Freyer

      Affiliations

    • Medical Oncology Unit, Centre Hospitalier Lyon-Sud, Pierre-Bénite, France
    • ,
  • Lena E. Friberg

      Affiliations

    • Uppsala University, Uppsala, Sweden
    • ,
  • Steven E. Kern

      Affiliations

    • College of Pharmacy, University of Utah, USA
    • ,
  • Annette Kopp-Schneider

      Affiliations

    • Department of Biostatistics, German Cancer Research Center, Heidelberg, Germany
    • ,
  • Wolf-Dieter Ludwig

      Affiliations

    • Robert-Rössle-Klinik Oncology and Tumorimmunology, Berlin-Buch, Germany
    • ,
  • Giuseppe De Nicolao

      Affiliations

    • Department of Computer Engineering and Systems Science, University of Pavia, Pavia, Italy
    • ,
  • Maurizio Rocchetti

      Affiliations

    • Accelera, Milan, Italy
    • ,
  • Iñaki F. Troconiz

      Affiliations

    • Departamento de Farmacia y Tecnología Farmacéutica, University Navarra, Pamplona, Spain

Received 16 April 2009 ,Revised 30 September 2009 ,Accepted 9 October 2009.

References 

  1. Natsoulis G, Pearson CI, Gollub J, et al. The liver pharmacological, xenobiotic gene response repertoire. Mol Syst Biol. 2008;4:175
  2. Ellinger-Ziegelbauer H, Stuart B, Wahle B, Bomann W, Ahr HJ. Characteristic expression profiles induced by genotoxic carcinogens in rat liver. Toxicol Sci. 2004;77(1):19–34
  3. Stemmer K, Ellinger-Ziegelbauer H, Ahr HJ, Dietrich DR. Carcinogen-specific gene expression profiles in short-term treated Eker and wild-type rats indicative of pathways involved in renal tumorigenesis. Cancer Res. 2007;67(9):4052–4068
  4. Oberemm A, Ellinger-Ziegelbauer H, Ahr HJ, et al. Comparative analysis of N-nitrosomorpholine-induced differential gene and protein expression in rat liver. Naunyn-Schmiedeberg’s Arch Pharmacol. 2007;375(Suppl. 1):92
  5. Oberemm A, Ahr HJ, Bannasch P, et al. Toxicogenomic analysis of N-nitrosomorpholine induced changes in rat liver: comparison of genomic and proteomic responses and anchoring to histopathological parameters. Toxicol Appl Pharmacol. 2009;
  6. Ellinger-Ziegelbauer H, Stuart B, Wahle B, Bomann W, Ahr HJ. Comparison of the expression profiles induced by genotoxic and nongenotoxic carcinogens in rat liver. Mutat Res. 2005;575(1–2):61–84
  7. Ellinger-Ziegelbauer H, Gmuender H, Bandenburg A, Ahr HJ. Prediction of a carcinogenic potential of rat hepatocarcinogens using toxicogenomics analysis of short-term in vivo studies. Mutat Res. 2008;637(1–2):23–39
  8. Fielden MR, Brennan R, Gollub J. A gene expression biomarker provides early prediction and mechanistic assessment of hepatic tumor induction by nongenotoxic chemicals. Toxicol Sci. 2007;99(1):90–100
  9. Fielden MR, Nie A, McMillian M, et al. Predictive safety testing consortium. Carcinogenicity Working Group; 2008.
  10. Nie AY, McMillian M, Parker JB, et al. Predictive toxicogenomics approaches reveal underlying molecular mechanisms of nongenotoxic carcinogenicity. Mol Carcinog. 2006;45(12):914–933
  11. Schneckener S, Görlitz L, Ellinger-Ziegelbauer H, Ahr HJ, Schuppert A. An elastic network theory to identify characteristic stress response genes, submitted for publication.
  12. Armitage P, Doll R. The age distribution of cancer and a multi-stage theory of carcinogenesis. Br J Cancer. 1954;8(1):1–12
  13. Kopp-Schneider A. Carcinogenesis models for risk assessment. Stat Methods Med Res. 1997;6(4):317–340
  14. Moolgavkar SH, Venzon DJ. Two-event model for carcinogenesis: Incidence curves for childhood and adult tumors. Math. Biosci. 1979;47:55–77
  15. Kopp-Schneider A, Portier CJ, Sherman CD. The exact formula for tumor incidence in the two-stage model. Risk Anal. 1994;14(6):1079–1080
  16. Heidenreich WF. On the parameters of the clonal expansion model. Radiat Environ Biophys. 1996;35(2):127–129
  17. Lutz WK, Kopp-Schneider A. Threshold dose response for tumor induction by genotoxic carcinogens modeled via cell-cycle delay. Toxicol Sci. 1999;49(1):110–115
  18. Moolgavkar SH, Luebeck EG, de Gunst M, Port RE, Schwarz M. Quantitative analysis of enzyme-altered foci in rat hepatocarcinogenesis experiments – I. Single agent regimen. Carcinogenesis. 1990;11(8):1271–1278
  19. Groos J, Kopp-Schneider A. Application of a color-shift model with heterogeneous growth to a rat hepatocarcinogenesis experiment. Math Biosci. 2006;202(2):248–268
  20. Kopp-Schneider A, Portier C, Bannasch P. A model for hepatocarcinogenesis treating phenotypical changes in focal hepatocellular lesions as epigenetic events. Math Biosci. 1998;148(2):181–204
  21. Croce CM. Oncogenes and cancer. N Engl J Med. 2008;358(5):502–511
  22. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57–70
  23. Verheul HM, Pinedo HM. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer. 2007;7(6):475–485
  24. Schiffer CA. BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia. N Engl J Med. 2007;357(3):258–265
  25. Deremer DL, Ustun C, Natarajan K. Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. Clin Ther. 2008;30(11):1956–1975
  26. Heinrich MC, Maki RG, Corless CL, et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol. 2008;26(33):5352–5359
  27. Antonescu CR. Targeted therapies in gastrointestinal stromal tumors. Semin Diagn Pathol. 2008;25(4):295–303
  28. Negri T, Bozzi F, Conca E, et al. Oncogenic and ligand-dependent activation of KIT/PDGFRA in surgical samples of imatinib-treated gastrointestinal stromal tumours (GISTs). J Pathol. 2009;217(1):103–112
  29. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129–2139
  30. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer – molecular and clinical predictors of outcome. N Engl J Med. 2005;353(2):133–144
  31. Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non-Hodgkin’s lymphoma. N Engl J Med. 2008;359(6):613–626
  32. Paik S, Kim C, Wolmark N. HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med. 2008;358(13):1409–1411
  33. Semenza GL. A new weapon for attacking tumor blood vessels. N Engl J Med. 2008;358(19):2066–2067
  34. Pro B, Leber B, Smith M, et al. Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma. Br J Haematol. 2008;143(3):355–360
  35. McCune JS, Gibbs JP, Slattery JT. Plasma concentration monitoring of busulfan: does it improve clinical outcome?. Clin Pharmacokinet. 2000;39(2):155–165
  36. Meille C, Iliadis A, Barbolosi D, Frances N, Freyer G. An interface model for dosage adjustment connects hematotoxicity to pharmacokinetics. J Pharmacokinet Pharmacodyn. 2008;35(6):619–633
  37. Henin E, You B, VanCutsem E, et al. A dynamic model of hand-and-foot syndrome in patients receiving capecitabine. Clin Pharmacol Ther. 2009;85(4):418–425
  38. Teicher BA. Tumor models for efficacy determination. Mol Cancer Ther. 2006;5(10):2435–2443
  39. Sausville EA, Burger AM. Contributions of human tumor xenografts to anticancer drug development. Cancer Res. 2006;66(7):3351–3354[discussion 3354]
  40. Kelland LR. Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development. Eur J Cancer. 2004;40(6):827–836
  41. Bajzer Z, Marusic M, Vuk-Pavlocic S. Conceptual frameworks for mathematical modeling of tumor growth dynamics. Math Comput Model. 1996;23:31–46
  42. Simeoni M, Magni P, Cammia C, et al. Predictive pharmacokinetic–pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents. Cancer Res. 2004;64(3):1094–1101
  43. Magni P, Simeoni M, Poggesi I, Rocchetti M, De Nicolao G. A mathematical model to study the effects of drugs administration on tumor growth dynamics. Math Biosci. 2006;200(2):127–151
  44. Mager DE, Jusko WJ. Mechanistic pharmacokinetic/pharmacodynamic models II. In:  Ette EI,  Williams PJ editor. Pharmacometrics: the science of quantitative pharmacology. John Wiley & Sons Inc.; 2007;p. 607–631
  45. Rocchetti M, Simeoni M, Pesenti E, De Nicolao G, Poggesi I. Predicting the active doses in humans from animal studies: a novel approach in oncology. Eur J Cancer. 2007;43(12):1862–1868
  46. Bueno L, de Alwis DP, Pitou C, et al. Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-beta kinase antagonist, in mice. Eur J Cancer. 2008;44(1):142–150
  47. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates?. Nat Rev Drug Discov. 2004;3(8):711–715
  48. Kamb A. What’s wrong with our cancer models?. Nat Rev Drug Discov. 2005;4(2):161–165
  49. Gurney H. How to calculate the dose of chemotherapy. Br J Cancer. 2002;86(8):1297–1302
  50. Burgess M, de Alwis DP. The true face of the revolution in oncology drug development. Curr Clin Pharmacol. 2007;2:31–36
  51. Blesch KS, Gieschke R, Tsukamoto Y, et al. Clinical pharmacokinetic/pharmacodynamic and physiologically based pharmacokinetic modeling in new drug development: the capecitabine experience. Invest New Drugs. 2003;21(2):195–223
  52. Tsukamoto Y, Kato Y, Ura M, et al. A physiologically based pharmacokinetic analysis of capecitabine, a triple prodrug of 5-FU, in humans: the mechanism for tumor-selective accumulation of 5-FU. Pharm Res. 2001;18(8):1190–1202
  53. Onodera H, Kuruma I, Ishitsuka H, Horii I. Pharmacokinetic study of capecitabine in monkeys and mice. Species differences in distribution of the enzymes responsible for its activation to 5-FU. Xenobiotic Metab Dispos. 2000;15:439–451
  54. Cassidy J, Twelves C, Van Cutsem E, et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol. 2002;13(4):566–575
  55. Bajetta E, Procopio G, Celio L, et al. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol. 2005;23(10):2155–2161
  56. Siegel-Lakhai WS, Zandvliet AS, Huitema AD, et al. A dose-escalation study of indisulam in combination with capecitabine (Xeloda) in patients with solid tumours. Br J Cancer. 2008;98(8):1320–1326
  57. Levi F, Altinok A, Clairambault J, Goldbeter A. Implications of circadian clocks for the rhythmic delivery of cancer therapeutics. Philos Transact A: Math Phys Eng Sci. 2008;366(1880):3575–3598
  58. Clairambault J. Modelling physiological and pharmacological control on cell proliferation to optimise cancer treatments. Math Model Nat Phenom. 2009;
  59. Bekkal-Brikci F, Clairambault J, Ribba B, Perthame B. An age-and-cyclin-structured cell population model for healthy and tumoral tissues. J Math Biol. 2008;57:91–110
  60. Bekkal-Brikci F, Clairambault J, Perthame B. Analysis of a molecular structured population model with polynomial growth for the cell cycle. Math Comp Model. 2008;47:699–713
  61. Goldbeter A. Biochemical oscillations and cellular rhythms. Cambridge, UK: Cambridge University Press; 1996;
  62. Leloup JC, Gonze D, Goldbeter A. Limit cycle models for circadian rhythms based on transcriptional regulation in Drosophila and Neurospora. J Biol Rhythm. 1999;14(6):433–448
  63. Leloup JC, Goldbeter A. Toward a detailed computational model for the mammalian circadian clock. Proc Natl Acad Sci USA. 2003;100(12):7051–7056
  64. Clairambault J. A step toward optimization of cancer therapeutics. Physiologically based modeling of circadian control on cell proliferation. IEEE-EMB Magazine. 2008;27:20–24
  65. Clairambault J. Modeling oxaliplatin drug delivery to circadian rhythm in drug metabolism and host tolerance. Adv Drug Deliv Rev. 2007;59:1054–1068
  66. Gore M, Mainwaring P, A’Hern R, et al. Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. London Gynaecological Oncology Group. J Clin Oncol. 1998;16(7):2426–2434
  67. Seidman AD. “Will weekly work”? Seems to be so. J Clin Oncol. 2005;23(25):5873–5874
  68. Tonini G, Schiavon G, Silletta M, Vincenzi B, Santini D. Antiangiogenic properties of metronomic chemotherapy in breast cancer. Future Oncol. 2007;3(2):183–190
  69. Sobrero AF, Aschele C, Bertino JR. Fluorouracil in colorectal cancer – a tale of two drugs: implications for biochemical modulation. J Clin Oncol. 1997;15(1):368–381
  70. Sandstrom M, Freijs A, Larsson R, et al. Lack of relationship between systemic exposure for the component drug of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients. J Clin Oncol. 1996;14(5):1581–1588
  71. Friberg LE, Karlsson MO. Schedule dependence in tumor response for 5-fluorouracil in colorectal cancer. In: American Conference of Pharmacometrics, 2008. Tuscon, Arizona, USA; 2008.
  72. Karlsson MO, Molnar V, Bergh J, Freijs A, Larsson R. A general model for time-dissociated pharmacokinetic–pharmacodynamic relationship exemplified by paclitaxel myelosuppression. Clin Pharmacol Ther. 1998;63(1):11–25
  73. Friberg LE, Brindley CJ, Karlsson MO, Devlin AJ. Models of schedule dependent haematological toxicity of 2′-deoxy-2′-methylidenecytidine (DMDC). Eur J Clin Pharmacol. 2000;56(8):567–574
  74. Friberg LE, Freijs A, Sandstrom M, Karlsson MO. Semiphysiological model for the time course of leukocytes after varying schedules of 5-fluorouracil in rats. J Pharmacol Exp Ther. 2000;295(2):734–740
  75. Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol. 2002;20(24):4713–4721
  76. Friberg LE, Hassan SB, Lindhagen E, Larsson R, Karlsson MO. Pharmacokinetic–pharmacodynamic modelling of the schedule-dependent effect of the anti-cancer agent CHS 828 in a rat hollow fibre model. Eur J Pharm Sci. 2005;25(1):163–173
  77. Claret L, Girard P, Zuideveld KP, et al. A longitudinal model for tumor size measurements in clinical oncology studies. In: Abstracts of the Annual Meeting of the Population Approach Group in Europe, 2006, p. 15. ISSN 1871-6032. Abstr 1004. <www.page-meeting.org/?abstract=1004>.
  78. Gennings C. An efficient experimental design for detecting departure from additivity in mixtures of many chemicals. Toxicology. 1995;105(2–3):189–197
  79. Short TG, Ho TY, Minto CF, Schnider TW, Shafer SL. Efficient trial design for eliciting a pharmacokinetic–pharmacodynamic model-based response surface describing the interaction between two intravenous anesthetic drugs. Anesthesiology. 2002;96(2):400–408
  80. Duffull S, Waterhouse T, Eccleston J. Some considerations on the design of population pharmacokinetic studies. J Pharmacokinet Pharmacodyn. 2005;32(3–4):441–457

☆ This paper is based in part on discussions at a COST B25 expert meeting held in Prague, Czech Republic, on 20–21st September 2007. Participating experts were Leon Aarons (UK), Hans-Jürgen Ahr (Germany), Jean Clairambault (France), Svein G. Dahl (Norway), Dinesh De Alwis (UK), Gilles Freyer (France), Lena Friberg (Sweden), Ursula Gundert Remy (Germany), Steve Kern (US), Anette Kopp-Schneider (Germany), Wolf-Dieter Ludwig (Germany), Jirina Martinkova (Czech Republic), Maurizio Rocchetti (Italy), Giuseppe De Nicolao (Italy), Jean-Louis Steimer (Switzerland), Iñaki F. Troconiz (Spain).

PII: S0959-8049(09)00758-8

doi: 10.1016/j.ejca.2009.10.011

European Journal of Cancer
Volume 46, Issue 1 , Pages 21-32 , January 2010

Article Tools

* Image Usage & Resolution